ClinicalTrials.gg
CompletedNCT01002573Updated Nov 7, 2016Results posted

Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients

A Phase 3 interventional study of ibuprofen and acetaminophen in Fever, sponsored by Cumberland Pharmaceuticals. Completed at 17 sites in United States. Open to participants aged Up to 16 Years. Per ClinicalTrials.gov, last updated 2016-11-07.

Sponsored by Cumberland Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
Up to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing ibuprofen in Fever — none open to participants now, none under way, none of them phase 3. Ibuprofen · Fever.

Enrollment
10th of 18
118 · median 119
Started
2010
with 1 other
Phase 3
6 of 19
none open now
Registered
6th of 19
by date
Lead sponsor
5 of 19
Cumberland Pharmaceuticals

Among the 19 studies testing ibuprofen in Fever, this one is the 10th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2010, is one of 6 in phase 3, and was the 6th registered.

Fever

438 studies on the registry are indexed under Fever; 55 are open to participants now.

Browse Fever studies →

Open to participants now

None of the 19 studies testing ibuprofen in Fever is open now. The open studies under Fever, anywhere →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 38 Fever studies recruiting now, 18 (47%) set no upper age limit and 14 (37%) stop at 75 or younger; 22 take children under 18; 11 take healthy volunteers.

This study: Up to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing ibuprofen in Fever as a file.
02

Study summary

The primary objective of the study is to determine the superiority of a single dose of intravenous ibuprofen compared to acetaminophen for the treatment of fever during the first two hours of treatment.

Read the detailed description

The primary objective of the study is to determine the superiority of a single dose of intravenous ibuprofen compared to acetaminophen for the treatment of fever as measured by the area under the change in temperature versus time curve during the first 2 hours of treatment.

03

Conditions studied

  • Fever

Browse trials for

Keywords

  • Pediatric
  • Fever
04

Who can participate

Ages eligible
Up to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have written provided by legal parent, guardian, or authorized agent prior to participation in the study or study-only related procedures.
  2. Be between birth (28 weeks to \< 40 weeks gestational age) to ≤ 16 years of age.
  3. Have new (less than 7 days) onset of fever, documented by temperature greater than or equal to 101.0 ºF (38.3 ºC).

Exclusion criteria

Exclusion Criteria:

  1. Have inadequate intravenous access.
  2. Have received antipyretic drug therapy within 2 hours before dosing.
  3. Have any history of allergy or to NSAIDs or aspirin.
  4. Have received another drug within the past 30 days.
  5. Be otherwise unsuitable for the study, in the opinion of the Investigator.
  6. Have a fever due to hyperthermia.
  7. Pregnant or nursing.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    ibuprofen

    Ibuprofen, 10 mg/kg

    Drug: ibuprofen

  • Active comparator
    Acetaminophen

    Acetaminophen, 10mg/kg

    Drug: acetaminophen

Interventions

  • Ibuprofen, 10 mg/kg

  • Acetaminophen, 10mg/kg

    Also known as: APAP (acetaminophen), paracetamol

06

What researchers measure

Primary outcomes

  1. Fever Reduction

    Treatment of fever as measured by the area under the change in temperature versus time curve during the first two hours of treatment (AUC0-2)

    Time frame: 0 to 2 hours post-dose

Secondary outcomes

  1. Change From Baseline in Temperature After the First 30 Minutes of Treatment

    Change in temperature in patients receiving intravenous ibuprofen and acetaminophen (APAP) after the first 30 minutes of treatment.

    Time frame: 30 minutes following treatment

  2. Change From Baseline in Temperature After the First 60 Minutes of Treatment

    Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 60 minutes of treatment.

    Time frame: 60 minutes following treatment

  3. Change in Temperature

    Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 4 hours of treatment.

    Time frame: 4 hours following treatment

  4. Change From Baseline in Temperature After the First Four Hours of Treatment

    Change in temperature during the first 4 hours of treatment by assessing the area under the change in temperature versus time curve during the first four hours of treatment (AUC0-4)

    Time frame: 0 to 4 hours post-dose

  5. Time to Afebrility (in Hours)

    Tme to afebrility (temperature less than 100.4 ºF \[38 ºC\]) in patients receiving intravenous ibuprofen and APAP.

    Time frame: 4 Hour post treatment

  6. Number of Afebrile and Febrile Subject at 4 Hours Post-Dose

    Number of Afebrile and Febrile Subject at 4 Hours Following Treatment

    Time frame: 4 Hours Post-Dose

07

Results

Posted Nov 7, 2016

Participant flow

Participant flow — Overall Study
MilestoneIbuprofenAcetaminophen
Started5860
Completed4753
Not completed117
Withdrew: Subject did not receive at least 1 dose117

Outcome measures

PrimaryFever Reduction

Treatment of fever as measured by the area under the change in temperature versus time curve during the first two hours of treatment (AUC0-2)

Time frame:
0 to 2 hours post-dose
Reported as:
Mean · degree Celsius*Time
Fever Reduction
degree Celsius*TimeIbuprofenAcetaminophen
Fever Reduction-1.5 ± 1.11-0.9 ± 0.89
SecondaryChange From Baseline in Temperature After the First 30 Minutes of Treatment

Change in temperature in patients receiving intravenous ibuprofen and acetaminophen (APAP) after the first 30 minutes of treatment.

Time frame:
30 minutes following treatment
Reported as:
Mean · Celsius
Change From Baseline in Temperature After the First 30 Minutes of Treatment
CelsiusIbuprofenAcetaminophen
Change From Baseline in Temperature After the First 30 Minutes of Treatment-0.5 ± 0.50-0.3 ± 0.49
SecondaryChange From Baseline in Temperature After the First 60 Minutes of Treatment

Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 60 minutes of treatment.

Time frame:
60 minutes following treatment
Reported as:
Mean · Celsius
Change From Baseline in Temperature After the First 60 Minutes of Treatment
CelsiusIbuprofenAcetaminophen
Change From Baseline in Temperature After the First 60 Minutes of Treatment-0.9 ± 0.69-0.5 ± 0.50
SecondaryChange in Temperature

Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 4 hours of treatment.

Time frame:
4 hours following treatment
Reported as:
Mean · Celsius
Change in Temperature
CelsiusIbuprofenAcetaminophen
Change in Temperature-1.5 ± 0.92-0.9 ± 0.92
SecondaryChange From Baseline in Temperature After the First Four Hours of Treatment

Change in temperature during the first 4 hours of treatment by assessing the area under the change in temperature versus time curve during the first four hours of treatment (AUC0-4)

Time frame:
0 to 4 hours post-dose
Reported as:
Mean · degree Celsius*Time
Change From Baseline in Temperature After the First Four Hours of Treatment
degree Celsius*TimeIbuprofenAcetaminophen
Change From Baseline in Temperature After the First Four Hours of Treatment-4.4 ± 2.59-2.6 ± 2.02
SecondaryTime to Afebrility (in Hours)

Tme to afebrility (temperature less than 100.4 ºF \[38 ºC\]) in patients receiving intravenous ibuprofen and APAP.

Time frame:
4 Hour post treatment
Reported as:
Mean · Hours
Time to Afebrility (in Hours)
HoursIbuprofenAcetaminophen
Time to Afebrility (in Hours)2.2 ± 0.473.3 ± 0.67
SecondaryNumber of Afebrile and Febrile Subject at 4 Hours Post-Dose

Number of Afebrile and Febrile Subject at 4 Hours Following Treatment

Time frame:
4 Hours Post-Dose
Reported as:
Number · participants
Number of Afebrile and Febrile Subject at 4 Hours Post-Dose
participantsIbuprofenAcetaminophen
Afebrile Subjects at 4 hours4340
Febrile at 4 Hours311

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibuprofen—2/47 (4.3%)28/47 (59.6%)
Acetaminophen—2/53 (3.8%)22/53 (41.5%)
Most frequent serious events
Most frequent serious events
EventIbuprofenAcetaminophen
PancreatitisGastrointestinal disorders1/470/53
PneumothoraxRespiratory, thoracic and mediastinal disorders1/470/53
Cardio-Respiratory ArrestCardiac disorders1/470/53
Transaminases IncreasedInvestigations1/470/53
Pleural EffusionRespiratory, thoracic and mediastinal disorders0/471/53
Abdoimnal AbscessInfections and infestations0/471/53
Most frequent other events
Showing 10 of 14
Most frequent other events
EventIbuprofenAcetaminophen
Infusion Site PainGeneral disorders5/470/53
DiarrhoeaGastrointestinal disorders1/474/53
VomitingGastrointestinal disorders3/473/53
NauseaGastrointestinal disorders3/472/53
HeadacheNervous system disorders3/471/53
Blood Lactate Dehydrogenase IncreasedInvestigations1/473/53
Aspartate Aminotransferase IncreasedInvestigations2/472/53
Alanine Aminotransferase IncreasedInvestigations2/471/53
Blood Albumin DecreasedInvestigations2/470/53
Oxygen Saturation DecreasedInvestigations2/470/53

Baseline characteristics

All Treated Subjects

Age, Customized
Age, Customized(participants)IbuprofenAcetaminophenTotal
6 months to 2 years61420
2 years to 6 years131427
6 years to 16 years282553
Sex: Female, Male
Sex: Female, Male(Participants)IbuprofenAcetaminophenTotal
Female202747
Male272653
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IbuprofenAcetaminophenTotal
Hispanic or Latino292453
Not Hispanic or Latino182947
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IbuprofenAcetaminophenTotal
American Indian or Alaska Native022
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American5813
White424284
More than one race000
Unknown or Not Reported011
08

Study locations

17 sites
  • Maricopa Medical Center
    Phoenix, Arizona 85008, United States
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • Howard University
    Washington D.C., District of Columbia 20060, United States
  • Jackson Memorial Hospital (U. Miami)
    Miami, Florida 33136, United States
  • Florida Hospital
    Orlando, Florida 32804, United States
  • Joseph M. Still Burn Center
    Augusta, Georgia 30909, United States
  • Kosair Children's Hospital
    Louisville, Kentucky 40202, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121-2483, United States
  • LSU Health Sciences Center
    Shreveport, Louisiana 71103, United States
  • Children's Hospital of Michigan
    Detroit, Michigan 48201, United States
  • Staten Island University Hospital
    Staten Island, New York 10305, United States
  • The Children's Hospital at Saint Francis
    Tulsa, Oklahoma 74136, United States
  • LeBonheur Children's Hospital
    Memphis, Tennessee 38103, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75235, United States
  • Children's Memorial Hermann Hospital
    Houston, Texas 77030, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Khalil SN, Hahn BJ, Chumpitazi CE, Rock AD, Kaelin BA, Macias CG. A multicenter, randomized, open-label, active-comparator trial to determine the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for treatment of fever in hospitalized pediatric patients. BMC Pediatr. 2017 Feb 1;17(1):42. doi: 10.1186/s12887-017-0795-y. PubMed 28143430 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 3 years 5 months after primary completion. A results delay was requested in Jul 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2009
First posted
Oct 27, 2009
Start
Jul 2010
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results delay requested
Jul 7, 2014
Results first posted
Nov 7, 2016
Last update
Nov 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01002573
Responsible party
Sponsor
First posted
Oct 27, 2009
Start date
Jul 2010
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Nov 7, 2016
Last update
Nov 7, 2016

Study contacts

Art Wheeler, M.D.
study director · Cumberland Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion